Analytical Data
-
Gene name
epd
- Application
-
Species
strain ATCC 7966
-
Source
E. coli
-
Tag
N- His & C- Myc
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
A0KGD2
-
Expression Region
1-336aa
-
Molecular Weight
44.3 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
EPD (Extracellular Protein Delivery) recombinant proteins have emerged as a significant focus in biotechnology and pharmaceutical research due to their potential in therapeutic applications. The study of EPD recombinant proteins is rooted in the need for effective protein delivery systems that can enhance the stability, solubility, and bioavailability of therapeutic proteins. Traditional methods of protein production often face challenges, such as low yields, improper folding, and degradation due to harsh conditions. By utilizing recombinant DNA technology, researchers can engineer host organisms, such as bacteria, yeast, or mammalian cells, to produce a wide range of proteins with high efficiency and correctness. These recombinant proteins can be modified post-translationally, allowing for enhanced functionality and targeting capabilities. The therapeutic potential of EPD recombinant proteins spans various fields, including the production of monoclonal antibodies, enzymes for metabolic disorders, and vaccines. As an integral part of modern medicine, advancements in the understanding of EPD mechanisms promote the design of novel protein-based therapies, addressing previously untreatable diseases. The continuous exploration of EPD recombinant proteins opens new avenues for developing more effective and personalized treatment options, highlighting their critical role in contemporary biomedicine and the ongoing quest for innovative health solutions.
